Dar Bioscience, Inc. and Premier Research International, LLC announced that the companies extended their partnership agreement under which Premier Research will continue to provide on an exclusive basis contract research organization (CRO) services within the United States to support the clinical development of Dar's reproductive health portfolio. The agreement was originally established with Health Decisions, Inc., which was acquired by Premier Research in 2021. In 2020, Dar and Premier Research conducted a successful Phase 3 clinical study of XACIATO (clindamycin phosphate) vaginal gel 2% despite the challenges posed by a global pandemic.

In exchange for that CRO exclusivity, Premier Research will continue to provide attractive pricing structures, clinical expertise, an extensive site network, relationships with key opinion leaders and investigators, and a core team of personnel dedicated to supporting all of Dar's development programs covered by the agreement.